- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01825902
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma
A Pilot Study of the Utility of 18F-FLT-PET and Diffusion-Weighted MRI for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Ewing Sarcoma Patients
Study Overview
Status
Conditions
- Ewing Sarcoma of Bone
- Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
- Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Extraosseous Ewing Sarcoma
Detailed Description
PRIMARY OBJECTIVES:
I. Establish correlation between 18F-FLT positron emission tomography (PET) activity, apparent diffusion coefficients (ADC) values from diffusion-weighted magnetic resonance imaging (DW-MRI), fludeoxyglucose F 18 (18F-FDG) PET activity, magnetic resonance imaging (MRI) contrast enhancement, and pathologic response for Ewing sarcoma.
II. Assess the efficacy of detecting therapy induced changes in 18F-FLT PET uptake and ADC from DW-MRI for more accurately predicting local control, event-free survival, and overall survival as compared to standard prognostic factors (e.g. change in tumor size).
III. Compare radiotherapy target volume delineation with pre- and post-chemotherapy 18F-FLT PET and DW-MRI information to delineation with pre-chemotherapy conventional MRI to determine role of advanced imaging in radiotherapy treatment planning for Ewing sarcoma.
SECONDARY OBJECTIVES:
I. Establish correlation between 18F-FLT PET activity, ADC values from DW-MRI, 18F-FDG PET activity, MRI contrast enhancement, and biomolecular assays for Ewing sarcoma.
II. Determine imaging thresholds to discriminate between viable and necrotic tumor, as established through pathologic correlations.
III. Assess efficacy of advanced imaging for more accurately guiding biopsy targeting by comparing planned targeting with standard (MRI contrast enhancement) vs. advanced imaging (18F -FLT PET and DW-MRI).
IV. Compare post-treatment response assessment with 18F-FLT PET and DW-MRI vs. 18F-FDG PET to determine whether 18F-FLT PET and ADC information is more accurate than 18F-FDG PET for distinguishing between necrosis and non-specific inflammation immediately following treatment.
V. Estimate potential reduction in acute and late side effects based on modified radiation therapy (RT) treatment volumes with pre- and post-chemotherapy 18F-FLT PET and DW-MRI information as compared to volumes delineated with pre-chemotherapy conventional MRI.
VI. Evaluate automatic image segmentation techniques for 18F-FLT PET and DW-MRI, comparing against biopsy determined imaging thresholds and expert Nuclear Medicine and MR Radiologist contours.
OUTLINE:
Patients undergo 18F-FLT PET, 18F-FDG PET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
After completion of study intervention, patients are followed up every 3 months for 1 year and then every 6 months for up to 4 years.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological confirmation of newly diagnosed localized or newly diagnosed with metastatic Ewing sarcoma (ES) or primitive neuroectodermal tumor (PNET) of bone or soft tissue
- Planning to receive definitive RT or surgery with or without adjuvant RT
- Willing to sign release of information for any follow-up records
- Provide informed written consent if >= 18 years; if < 18 years, provide informed written assent and parent or legal guardian provide informed written consent
- Patients must have measurable disease
- Willingness to participate in mandatory imaging studies
- Willingness to provide mandatory pathology samples for correlative research
Exclusion Criteria:
- Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure)
- Unable to undergo 18F-FLT PET scan
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)
Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
|
Correlative studies
Undergo DW-MRI
Other Names:
Undergo 18F-FLT PET
Other Names:
Undergo 18F-FDG PET
Other Names:
Undergo 18F-FLT PET and 18F-FDG PET
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
18F-FLT PET activity
Time Frame: At the time of surgical resection
|
The primary measure of the samples will be % of viable malignant cells remaining.
To examine the correlation of 18F-FLT PET, 18F-FDG PET, and ADC signals in areas of concordance and discordance with standard MR imaging as it impacts differentiation of viable and necrotic tumor extent, sensitivity/specificity and positive/negative predictive values will be estimated.
Findings will be summarized using point-estimates and corresponding 95% confidence intervals as appropriate.
Differences in sensitivity and specificity will be evaluated using McNemar's test.
|
At the time of surgical resection
|
ADC values from DW-MRI
Time Frame: At the time of surgical resection
|
The primary measure of the samples will be % of viable malignant cells remaining.
To examine the correlation of 18F-FLT PET, 18F-FDG PET, and ADC signals in areas of concordance and discordance with standard MR imaging as it impacts differentiation of viable and necrotic tumor extent, sensitivity/specificity and positive/negative predictive values will be estimated.
Findings will be summarized using point-estimates and corresponding 95% confidence intervals as appropriate.
Differences in sensitivity and specificity will be evaluated using McNemar's test.
|
At the time of surgical resection
|
18F-FDG PET activity
Time Frame: At the time of surgical resection
|
The primary measure of the samples will be % of viable malignant cells remaining.
To examine the correlation of 18F-FLT PET, 18F-FDG PET, and ADC signals in areas of concordance and discordance with standard MR imaging as it impacts differentiation of viable and necrotic tumor extent, sensitivity/specificity and positive/negative predictive values will be estimated.
Findings will be summarized using point-estimates and corresponding 95% confidence intervals as appropriate.
Differences in sensitivity and specificity will be evaluated using McNemar's test.
|
At the time of surgical resection
|
MRI contrast enhancement
Time Frame: At the time of surgical resection
|
The primary measure of the samples will be % of viable malignant cells remaining.
To examine the correlation of 18F-FLT PET, 18F-FDG PET, and ADC signals in areas of concordance and discordance with standard MR imaging as it impacts differentiation of viable and necrotic tumor extent, sensitivity/specificity and positive/negative predictive values will be estimated.
Findings will be summarized using point-estimates and corresponding 95% confidence intervals as appropriate.
Differences in sensitivity and specificity will be evaluated using McNemar's test.
|
At the time of surgical resection
|
Pathologic response
Time Frame: At the time of surgical resection
|
The primary measure of the samples will be % of viable malignant cells remaining.
To examine the correlation of 18F-FLT PET, 18F-FDG PET, and ADC signals in areas of concordance and discordance with standard MR imaging as it impacts differentiation of viable and necrotic tumor extent, sensitivity/specificity and positive/negative predictive values will be estimated.
Findings will be summarized using point-estimates and corresponding 95% confidence intervals as appropriate.
Differences in sensitivity and specificity will be evaluated using McNemar's test.
|
At the time of surgical resection
|
18F-FLT PET and DW-MRI in predicting local control, event-free survival, and overall survival, measured by therapy-induced changes in the scans
Time Frame: Up to 5 years
|
The prognostic ability of 18F-FLT PET and DW-MRI imaging will be evaluated by correlating changes in 18F-FLT uptake and ADC as treatment response both after chemotherapy (but prior to RT) and after RT with local control and survival outcomes, with the intent of establishing predictive thresholds.
The results will be compared to standard prognostic factors such as change in tumor size and histopathology.
|
Up to 5 years
|
Radiotherapy target volume delineation with pre- and post-chemotherapy 18F-FLT PET and DW-MRI
Time Frame: Up to 5 years
|
PET images and DW-MRI ADC maps co-registered and regions of concordance and discordance quantified for each modality as compared to pre-chemotherapy conventional MRI.
The concordance correlation coefficient will be used to measure agreement between volumes generated at different times, with different modalities, and by different individuals.
The measured variability associated with contrast-enhanced MRI will serve as the standard for comparison.
The mean and standard deviation of volumes and their discordances will be calculated as a measure of the potential treatment impact of each modality.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Imaging thresholds
Time Frame: Up to 1 week after completion of chemotherapy and radiation therapy
|
Imaging thresholds to discriminate between > 90% and 100% necrotic tumor as established by pathology will be determined.
|
Up to 1 week after completion of chemotherapy and radiation therapy
|
Efficacy of advanced imaging in accurately guiding biopsy, measured by differences in determining target location by contrast enhancement or 18F-FLT PET and DW-MRI
Time Frame: At the time of surgery/biopsy
|
At the time of surgery/biopsy
|
|
Accuracy in distinguishing between necrosis and non-specific inflammation immediately following treatment
Time Frame: Up to 5 years
|
Treatment response as measured by the advanced imaging immediately following treatment will be compared to response as measured by conventional 18F-FDG PET follow-up imaging.
In the case of local recurrence, patterns of local failure will be compared with imaging performed before and after local therapy.
|
Up to 5 years
|
Reduction in acute side effects based on modified RT treatment volumes with pre- and post-chemotherapy 18F-FLT PET and DW-MRI as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time Frame: Within 7 days after completion of RT
|
For each patient the portion of the treated volume that is negative on PET or DW-MRI will be calculated to estimate the region of additional normal tissue that could be excluded from radiation treatment fields.
Similarly, any volume that is positive on PET or DW-MRI, but outside of the post-chemotherapy treatment volume will be reported.
|
Within 7 days after completion of RT
|
Reduction in late side effects based on modified RT treatment volumes with pre- and post-chemotherapy 18F-FLT PET and DW-MRI as assessed by the NCI CTCAE 4.0 version
Time Frame: Up to 5 years
|
For each patient the portion of the treated volume that is negative on PET or DW-MRI will be calculated to estimate the region of additional normal tissue that could be excluded from radiation treatment fields.
Similarly, any volume that is positive on PET or DW-MRI, but outside of the post-chemotherapy treatment volume will be reported.
|
Up to 5 years
|
Automatic image segmentation techniques for 18F-FLT PET and DW-MRI
Time Frame: Up to 5 years
|
To develop a standardized delineation technique for the 18F-FLT PET and DW-MRI images and reduce operator error and subjectivity, the variation of volumes defined with different segmentation techniques will be evaluated and compared against the biopsy determined imaging thresholds and expert Nuclear Medicine and MR Radiologist contours.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Osteosarcoma
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Sarcoma
- Sarcoma, Ewing
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Molecular Mechanisms of Pharmacological Action
- Radiopharmaceuticals
- Fluorodeoxyglucose F18
Other Study ID Numbers
- MC1279
- NCI-2013-00707 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ewing Sarcoma of Bone
-
Italian Sarcoma GroupRecruiting
-
Institute of Mother and Child, Warsaw, PolandMaria Sklodowska-Curie National Research Institute of OncologyRecruitingOsteosarcoma | Ewing Sarcoma of BonePoland
-
Children's Cancer Hospital Egypt 57357CompletedOsteosarcoma | Ewing Sarcoma of BoneEgypt
-
Istituto Ortopedico RizzoliCompleted
-
Mayo ClinicRecruitingEwing Sarcoma of Bone | Chondrosarcoma | Chordoma | Bone Sarcoma | Pelvic RhabdomyosarcomaUnited States
-
Institut CurieUNICANCERCompletedEwing Sarcoma Family of TumorsFrance
-
Istituto Ortopedico RizzoliRegione Emilia-RomagnaCompletedEwing Sarcoma Family of TumorsUnited Kingdom, Italy
-
Dana-Farber Cancer InstituteHarvard University; Conquer Cancer Foundation; Alex's Lemonade Stand Foundation; Sam Day FoundationRecruitingEwing Sarcoma of Bone | Ewing Sarcoma | Peripheral Primitive Neuroectodermal Tumor | Peripheral Primitive Neuroectodermal Tumor of Bone | High-grade Osteosarcoma | Ewing Sarcoma of Soft Tissue | Peripheral Primitive Neuroectodermal Tumor of Soft TissueUnited States
-
University of OxfordAstellas Pharma Inc; European Organisation for Research and Treatment of Cancer... and other collaboratorsCompletedRefractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited Kingdom, Germany, Netherlands, Italy, France
-
PfizerCompletedEwing's Sarcoma Family of TumorsSpain, France, United States, Italy, Australia, Germany, United Kingdom, Israel, Canada, Brazil, Chile
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States